lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Successful Transitioning Children and Adolescents with Type 1 Diabetes from Multiple Daily Injections to Advanced Hybrid Closed Loop System in 10 Days: A Prospective Intervention Study on MiniMed 780G System

20 Pages Posted: 10 Jun 2021

See all articles by Goran Petrovski

Goran Petrovski

Sidra Medicine - Division of Endocrinology and Diabetes

Fawziya Al Khalaf

Sidra Medicine

Judith Campbell

Sidra Medicine - Division of Endocrinology and Diabetes

Emma Day

Sidra Medicine

Douha Almajaly

Sidra Medicine

Khalid Hussain

Sidra Medicine - Division of Endocrinology and Diabetes

Maheen Pasha

Sidra Medicine

Fareeda Umer

Sidra Medicine

Manar Hamdan

Sidra Medicine

Amel Khalifa

Sidra Medicine

More...

Abstract

Background: Advanced Hybrid Closed Loop (AHCL) systems provide superior glycemic control in   children and adolescents with Type 1 Diabetes (T1D). Current studies included participants with previous pump and Continuous Glucose Monitoring (CGM) experience. We aimed to study transitioning these patients on Multiple Daily Injections (MDI) without prior pump experience to AHCL systems within a short period, utilizing a structured initiation protocol and the glycemic control they achieved with the MiniMed 780G system.

Methods: In this prospective open label single-arm, single-center, clinical investigation, we recruited children and adolescents (aged 7-17 years) with T1D on MDI therapy and HbA1c below 12.5% from Sidra Medicine (Doha, Qatar). All participants followed a structured initiation protocol including 4 steps: step 1: AHCL system assessment (1 hour discussion with educator); step 2: AHCL system training (2-hours sessions in 4 consecutive days with groups of 2 to 3 participants and caregivers); step 3: SAP use for 3 days; step 4: AHCL system use for 12 weeks, cumulating in 10 days from MDI to AHCL initiation. The primary outcome of the study was the change in the time spent in the target in range (TIR) of 70-180 mg/dl and HbA1c from baseline (MDI + CGM, 1 week) to study phase (AHCL, 12 weeks). This study is registered with ClinicalTrials.gov, number NCT04308291, and is completed.

Findings: Between October 25, 2020, and February 5, 2021, 34 participants were recruited and all of them completed the 12 weeks study. TIR increased from 42.1±18.7% at baseline to 78.8±6.1% in the study phase ( p <0.001). HbA1c decreased from 8.6±1.7% (70±18.6 mmol/mol) at baseline, to 6.5±0.7% (48±7.7 mmol/mol) at the end of the study ( p =0.001). The participants used the sensor for a median of 96% of the time and spent a median of 90% in AHCL during the 12 weeks. No episodes of severe hypoglycemia or DKA were reported.

Interpretation: Children and adolescents with T1D on MDI therapy who initiated the AHCL system following a 10-days structured protocol achieved the internationally recommended goals of glycemic control with TIR >70% and a HbA1c of <7%.

Clinical Trial Registration: This study is registered with ClinicalTrials.gov, number NCT04308291, and is completed.

Funding: This study was funded by Sidra Medicine in Doha, Qatar.

Declaration of Interest: Authors declare no competing interests.

Ethical Approval: The study was approved by the local and National Ethics Committee in Qatar and all participants, and their guardians signed a written informed assent/consent before the start of study-related procedures.

Keywords: Type 1 Diabetes, Continuous Subcutaneous Insulin Infusion, Continuous Glucose Monitoring, Diabetes Education, Closed-loop systems

Suggested Citation

Petrovski, Goran and Al Khalaf, Fawziya and Campbell, Judith and Day, Emma and Almajaly, Douha and Hussain, Khalid and Pasha, Maheen and Umer, Fareeda and Hamdan, Manar and Khalifa, Amel, Successful Transitioning Children and Adolescents with Type 1 Diabetes from Multiple Daily Injections to Advanced Hybrid Closed Loop System in 10 Days: A Prospective Intervention Study on MiniMed 780G System. Available at SSRN: https://ssrn.com/abstract=3864081 or http://dx.doi.org/10.2139/ssrn.3864081

Goran Petrovski (Contact Author)

Sidra Medicine - Division of Endocrinology and Diabetes ( email )

Doha
Qatar

Fawziya Al Khalaf

Sidra Medicine

Doha
Qatar

Judith Campbell

Sidra Medicine - Division of Endocrinology and Diabetes

Doha
Qatar

Emma Day

Sidra Medicine

Douha Almajaly

Sidra Medicine

Doha
Qatar

Khalid Hussain

Sidra Medicine - Division of Endocrinology and Diabetes

Doha
Qatar

Maheen Pasha

Sidra Medicine

Doha
Qatar

Fareeda Umer

Sidra Medicine

Doha
Qatar

Manar Hamdan

Sidra Medicine

Doha
Qatar

Amel Khalifa

Sidra Medicine

Doha
Qatar